Cypress Funds’s Gilead Sciences GILD Stock Holding History

Cypress Funds’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-91,000	Closed	-$6.18M	–	25
2017 Q1	$6.18M	Buy	+91,000	New	+$6.4M	1.29%	23

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cypress Funds's GILD Position: Q2 2017 in Review

Cypress Funds sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 91,000 shares — an estimated $6.18M sold.

Cypress Funds first reported a position in GILD in Q1 2017 and held it in 1 quarter. The position peaked at $6.18M in Q1 2017. 1,519 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

Cypress Funds reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
Cypress Funds sold 91,000 Gilead Sciences shares in Q2 2017, an estimated $6.18M.
Cypress Funds first reported a position in Gilead Sciences in Q1 2017 and held it in 1 quarter.
Cypress Funds's Gilead Sciences position peaked at $6.18M in Q1 2017.
1,519 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Cypress Funds's 13F filing for Q2 2017, filed 25 Jul 2017.